Are lipid-lowering guidelines evidence-based?

Lancet

Volumn 369, Issue 9557, 2007, Pages 168-169

  Abramson, J ^a   Wright, JM ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; STATIN;

ARTICLE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 33846239296     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60084-1     Document Type: Note

References (9)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (adult treatment panel III) final report: table II.2-3 (September, 2002). http://www.nhlbi.nih.gov/guidelines/cholesterol (accessed Jan 2, 2007).
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Adult treatment panel III, final report (September, 2002). http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf (accessed Jan 2, 2007).
3. Savoie I., and Kazanjian A. Utilization of lipid-lowering drugs in men and women: a reflection of the research evidence?. J Clin Epidemiol 55 (2002) 95-101
4. Jauca C., and Wright J. Therapeutics letter: update on statin therapy. Int Soc Drug Bull Newsletter 17 (2003) 7-9
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
6. Walsh J., and Pigame M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
7. Shepherd J., Blauw G., Murphy M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
8. Chiuve S., McCullough M., Sacks F., and Rimm E. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid lowering and antihypertensive medications. Circulation 114 (2006) 160-167
9. Manuel D., Kwong K., Tanuseputro P., et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 332 (2006) 1419-1422